Raymond James Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $140
Raymond James analyst Thomas Deal initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and announces Price Target of $140.
Share
Why It Matters
A big investment bank believes Kymera could do really well ahead. When new experts like this company, it shows they think the business is strong.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.